Ivermectin does not speed recovery time from unusual covid

Adding further evidence that the antiparasitic drug ivermectin is ineffective as a COVID-19 treatment, preliminary results from an ongoing randomized, controlled clinical trial Repurposed medicine today clothes It has been shown not to speed recovery in patients with mild to moderate infections.

Ivermectin, which is used worldwide to treat human worm infections and parasitic animal infections, has been investigated as a treatment for COVID-19 after an in vitro study suggested antiviral activity, but lacks evidence of benefit.

Three days of treatment or placebo

A team led by the Duke Clinical Research Institute led the remote, double-blind platform trial involving 1,591 non-hospitalized COVID-19 patients aged 30 years and older who had a one-week or less period from June 23, 2021 to February 4. There were at least two symptoms for , 2022, at 93 US sites. Follow-up continued until 31 May. The study period spanned the period of dominance of delta and omicron variants.

Participants were randomly assigned to receive 400-microgram-per-kilogram tablets of ivermectin (817 patients) or a placebo (774) for 3 days. They completed daily symptom and adverse-event assessments via a study portal for 14 days, then at variable intervals between 28 days and 90 days.

The median age was 48 years, 58.6% were female, 81% were white, 10% were Hispanic, 7% were black, and 47.3% reported receiving two or more doses of the Covid-19 vaccine. The median time from symptom onset to study drug receipt was 6 days. Chronic conditions were common, including obesity (41%), diabetes (11.5%), hypertension (26%), asthma (15%), and chronic obstructive pulmonary disease (4%).

Ivermectin ‘not supported’

The hazard ratio (HR) for rapid recovery was 1.07 (95% confidence interval). [CrI], 0.96 to 1.17; posterior probability of benefit, .91), indicating no benefit. The median time to recovery (at least 3 consecutive days without symptoms) was 12 days in the ivermectin group and 13 days in the placebo group.

Ten participants in the ivermectin group and nine placebo recipients were hospitalized (1.2% each; HR, 1.1), while 3.9% of the former and 3.6% of the latter visited an urgent care center or emergency department, were hospitalized, or died. One ivermectin recipient died.

Adverse events were uncommon and similar in the two groups (2.8% in the ivermectin group vs. 3.5% in the placebo group). The most common serious adverse events were COVID-19 pneumonia (five in the ivermectin group, seven in the placebo group) and venous thromboembolism (a blood clot in a vein) (one and five, respectively).

“In outpatients with mild to moderate COVID-19, treatment with ivermectin did not significantly improve recovery time compared with placebo,” the study authors wrote. “A lack of treatment effect was also observed for secondary clinical outcomes, including hospitalization, death, or acute care visits. These results do not support the use of ivermectin in patients with mild to moderate Covid-19.”